Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.
Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health and more research on other diseases.
Biotechnology company Moderna Inc. (NASDAQ ... to treat infectious diseases like RSV, Zika, and HIV, as well as help create cancer vaccines. However, the company has struggled to diversify ...
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback